Nature Communications (Aug 2024)

Atypical and non-classical CD45RBlo memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19

  • David G. Priest,
  • Takeshi Ebihara,
  • Janyerkye Tulyeu,
  • Jonas N. Søndergaard,
  • Shuhei Sakakibara,
  • Fuminori Sugihara,
  • Shunichiro Nakao,
  • Yuki Togami,
  • Jumpei Yoshimura,
  • Hiroshi Ito,
  • Shinya Onishi,
  • Arisa Muratsu,
  • Yumi Mitsuyama,
  • Hiroshi Ogura,
  • Jun Oda,
  • Daisuke Okusaki,
  • Hisatake Matsumoto,
  • James B. Wing

DOI
https://doi.org/10.1038/s41467-024-50997-4
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Resting memory B cells can be divided into classical or atypical groups, but the heterogenous marker expression on activated memory B cells makes similar classification difficult. Here, by longitudinal analysis of mass cytometry and CITE-seq data from cohorts with COVID-19, bacterial sepsis, or BNT162b2 mRNA vaccine, we observe that resting B cell memory consist of classical CD45RB+ memory and CD45RBlo memory, of which the latter contains of two distinct groups of CD11c+ atypical and CD23+ non-classical memory cells. CD45RB levels remain stable in these cells after activation, thereby enabling the tracking of activated B cells and plasmablasts derived from either CD45RB+ or CD45RBlo memory B cells. Moreover, in both COVID-19 patients and mRNA vaccination, CD45RBlo B cells formed the majority of SARS-CoV2 specific memory B cells and correlated with serum antibodies, while CD45RB+ memory are activated by bacterial sepsis. Our results thus identify that stably expressed CD45RB levels can be exploited to trace resting memory B cells and their activated progeny, and suggest that atypical and non-classical CD45RBlo memory B cells contribute to SARS-CoV-2 infection and vaccination.